Drugs

, Volume 73, Issue 2, pp 117–130 | Cite as

Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease

Leading Article

Abstract

Erythropoiesis-stimulating agents (ESAs) have become a hallmark of anaemia therapy in patients with chronic kidney disease (CKD). Although different ESAs are available for the treatment of renal anaemia, each nephrologist should select a single ESA for an individual patient. Epoetin alfa and epoetin beta have been used 1–3 times weekly but extended-interval dosing up to every 4 weeks is also effective in a substantial majority of CKD patients. However, the epoetin dose necessary to achieve or maintain target haemoglobin (Hb) levels increases substantially as the dosing interval increases. Subcutaneous administration of short-acting ESAs is more effective than the intravenous route of administration. Darbepoetin alfa and the continuous erythropoietin receptor activator (CERA) have been developed as a treatment for anaemia with extended administration intervals (every 2 weeks and every 4 weeks, respectively). Dose requirements for these long-acting ESAs are independent of the route of administration. Patents of short-acting ESAs have expired, which has opened the field for biosimilars. Epoetin biosimilars approved by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) have been shown to have a comparable efficacy and safety profile to their originators. An alarming increase in pure red cell aplasia (PRCA) in Thailand with follow-on epoetins manufactured in Asia (but also those manufactured in Latin America) indicates that stringent country-specific approval and pharmacovigilance protocols for ESAs manufactured in non-North American and non-EU European countries are urgently needed. Two PRCA cases occurring with subcutaneous HX575 (one certain, one likely) indicate that chances of inducing a more immunogenic product are unpredictable, even with a biosimilar epoetin approved under the EMA biosimilar approval pathway. Phase III clinical trials with peginesatide, a pegylated synthetic peptide-based ESA without any homology to erythropoietin raised safety concerns in non-dialysis CKD patients but not in dialysis patients.

Notes

Acknowledgments

No sources of funding were used to conduct this study or prepare this manuscript. Professor Walter H. Hörl has associations with the following companies: Amgen (speakers’ bureau), Sandoz (consultant), Hexal (consultant, speakers’ bureau), Fresenius (speakers’ bureau, research support), Vifor (consultant, speakers’ bureau, grant/research support), Medice (speakers’ bureau), Abbott (speakers’ bureau) and Takeda (consultant).

References

  1. 1.
    Jelkmann W. Molecular biology of erythropoietin. Intern Med. 2004;43:649–59.PubMedGoogle Scholar
  2. 2.
    Deicher R, Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs. 2004;64:499–509.PubMedGoogle Scholar
  3. 3.
    Locatelli F, Covic A, Eckardt KU, et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009;24:348–54.PubMedGoogle Scholar
  4. 4.
    Spinowitz B, Germain M, Benz R, et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:935–7.Google Scholar
  5. 5.
    Piccolo AM, Malagoli A, Komninos G, et al. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. J Nephrol. 2002;15:565–74.Google Scholar
  6. 6.
    Provenzano R, Bhaduri S, Singh AK, et al. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease. The PROMPT study. Clin Nephrol. 2005;64:113–23.PubMedGoogle Scholar
  7. 7.
    Lim VS, Kirchner PT, Fangman J, et al. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis. 1989;14:496–506.PubMedGoogle Scholar
  8. 8.
    Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol. 2004;61:392–405.PubMedGoogle Scholar
  9. 9.
    Benz R, Schmidt R, Kelly K, et al. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:215–21.PubMedGoogle Scholar
  10. 10.
    Germain M, Ram CV, Bhaduri S, et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant. 2005;20:2146–52.PubMedGoogle Scholar
  11. 11.
    Pergola P, Gartenberg G, Fu M, et al. A randomized controlled study of weekly and every-2-week dosing of epoetin alfa in CKD patients with anemia. Clin J Am Soc Nephrol. 2009;4:1731–40.PubMedGoogle Scholar
  12. 12.
    Pergola PE, Gartenberg G, Fu M, et al. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Clin J Am Soc Nephrol. 2010;5:598–606.PubMedGoogle Scholar
  13. 13.
    Gobin J, Cernii A. Mc Lean R et al. Conversion from epoetin alfa to darbepoetin alfa for management of anemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig. 2011;31:113–20.PubMedGoogle Scholar
  14. 14.
    Jelkmann W. Biosimilar epoetins and other “follow-on” biologics: update of the European experiences. Am J Hematol. 2010;85:771–80.PubMedGoogle Scholar
  15. 15.
    European Public Assessment Report (EPAR). Eporatio® [online]. Available from URL: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001033/human_med_001204.jsp [Accessed 2012 Nov 26].
  16. 16.
    Gertz B, Kes P, Essaian A, et al. Epoetin alfa: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta. Curr Med Res Opin. 2012;28:1101–10.PubMedGoogle Scholar
  17. 17.
    Sörgel F, Thyroff-Frieslinger U, Vetter A, et al. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol. 2009;9:10.PubMedGoogle Scholar
  18. 18.
    Sörgel F, Thyroff-Friesinger U, Vetter A, et al. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharmacol. 2009;47:391–401.Google Scholar
  19. 19.
    Haag-Weber M, Vetter A, Thyroff-Friesinger U, et al. Therapeutic equivalence, long-term and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009;72:380–90.PubMedGoogle Scholar
  20. 20.
    Hörl WH, Locatelli F, Haag-Weber M, et al. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10–12 g/dl. Clin Nephrol. 2012;78:24–32.PubMedGoogle Scholar
  21. 21.
    Haag-Weber M, Eckardt K-U, Hörl WH, et al. Safety, immunogenicity of subcutaneous biosimilar epoetin alfa (HX575) in non-dialysis patients with renal anaemia: a multi-centre, randomised, double-blind study. Clin Nephrol. 2012;77:8–17.PubMedGoogle Scholar
  22. 22.
    Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Drugs. 2011;11:61–75.Google Scholar
  23. 23.
    Macdougall IC, Roger S, De Francisco A, et al. Antibody-mediated pure red cell aplasia in patients receiving ESA therapy: new insights. Kidney Int. 2012;81:727–32.PubMedGoogle Scholar
  24. 24.
    Seidl A, Hainzl O, Richter M, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packing as a cause of immunogenicity. Pharm Res. 2012;29:1454–67.PubMedGoogle Scholar
  25. 25.
    Van Beers MM, Jiskoot W, Schellekens H. On the role of aggravates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res. 2010;30:767–75.PubMedGoogle Scholar
  26. 26.
    Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol. 2006;3:123–30.PubMedGoogle Scholar
  27. 27.
    Ryan MH, Heavner GA, Brigham-Burke M, et al. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunpharmacol. 2006;6:647–55.Google Scholar
  28. 28.
    Jiang Y, Nashed-Samuel Y, Li C, et al. Tungsten-induced protein aggregation: solution behaviour. J Pharm Sci. 2009;98:4765–70.Google Scholar
  29. 29.
    Bee JS, Nelson SA, Freund E, et al. Precipitation of a monoclonal antibody to soluble tungsten. J Pharm Sci. 2009;98:3290–301.PubMedGoogle Scholar
  30. 30.
    Liu W, Swift R, Torraca G, et al. Root cause analysis of tungsten-induced protein aggregation in pure-filled syringes. PDA J Pharm Sci Tech. 2010;64:11–9.Google Scholar
  31. 31.
    Wizemann V, Rutkowski B, Baldamus C, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24:625–37.PubMedGoogle Scholar
  32. 32.
    Krivoshiev S, Todorov VV, Manitius J, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin. 2008;24:1407–15.PubMedGoogle Scholar
  33. 33.
    Krivoshiev S, Wizemann V, Czekalski S, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010;27:105–17.PubMedGoogle Scholar
  34. 34.
    Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology: a single-dialysis center experience. Clin Nephrol. 2011;75:59–62.PubMedGoogle Scholar
  35. 35.
    Brinks V, Hawe A, Basmeleh AH, et al. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28:386–9.PubMedGoogle Scholar
  36. 36.
    Hörbrand F, Bramlage P, Fischaleck J, et al. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol. Epub 2012 Oct 2.Google Scholar
  37. 37.
    Abraham I, MacDonald K. Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf. 2012;11:819–40.PubMedGoogle Scholar
  38. 38.
    Goldsmith D. 2009: a requiem for rHuEPOs: but should we nail down the coffin in 2010? Clin J Am Soc Nephrol. 2010;5:929–35.Google Scholar
  39. 39.
    Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 2008;74:1617–22.PubMedGoogle Scholar
  40. 40.
    Schellekens H. The first biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol. 2008;3:174–8.PubMedGoogle Scholar
  41. 41.
    Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005;25:954–62.PubMedGoogle Scholar
  42. 42.
    Praditpornsilpa K, Tiranathanagul K, Kupawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80:88–92.PubMedGoogle Scholar
  43. 43.
    Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis. 2009;16:117–30.PubMedGoogle Scholar
  44. 44.
    Perez-Oliva JF, Casanova-Gonzales M, Garcia-Garcia I, et al. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel randomized, double blind study. BMC Nephrol. 2005;6:1–11.Google Scholar
  45. 45.
    Bock HA, Hirt-Minkowski P, Brunisholz M, et al. Darbepoetin alpha in lower-than-equimolar dosis maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant. 2008;23:301–8.PubMedGoogle Scholar
  46. 46.
    Tanakitcharu P, Siriwiwatanakul N. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia. J Med Assoc Thai. 2007;90:2574–86.Google Scholar
  47. 47.
    Metivier F, Marchais SJ, Guerin AP, et al. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000;15(Suppl. 3):14–8.PubMedGoogle Scholar
  48. 48.
    Park SS, Park J, Ko J, et al. Biochemical assessment of erythropoietin products from Asia versus US epoetin alfa manufactured by Amgen. J Pharm Sci. 2008;98:1688–99.Google Scholar
  49. 49.
    Schmidt CA, Ramos AS, da Silva JEP, et al. Availiaco da atividade e caracterizacão de erithropoietin a humana recombinante em produtos farmacéuticos. Arq Bras Endocrinol Metabol. 2003;47:183–9.Google Scholar
  50. 50.
    Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm. 2004;3:43–7.Google Scholar
  51. 51.
    Wish JB. Erythropoiesis-stimulating agents and pure red-cell aplasia: you can’t fool mother nature. Kidney Int. 2011;80:11–3.PubMedGoogle Scholar
  52. 52.
    Schellekens H. Follow-on biologics challenges of the next generation. Nephrol Dial Transplant 2005; 20 Suppl. 4: iv31–6.Google Scholar
  53. 53.
    Roger SD, Goldsmith D. Biosimilars: it’s not as simple as cost alone. J Clin Pharm Ther. 2008;33:459–64.PubMedGoogle Scholar
  54. 54.
    Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther. 2010;10:1–8.Google Scholar
  55. 55.
    Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84(Suppl. 1):3–10.PubMedGoogle Scholar
  56. 56.
    Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392–5.PubMedGoogle Scholar
  57. 57.
    Doshi S, Chow A, Pérez Ruixo JJ. Exposure-response modelling of darbepoetin alfa in anemic patiens with chronic kidney disease not receiving dialysis. J Clin Pharmacol. 2010;50:755–905.Google Scholar
  58. 58.
    Aarup M, Bryndum J, Dieperink H, et al. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant. 2006;21:1312–6.PubMedGoogle Scholar
  59. 59.
    Sharma A, Yee J, Gandra SR, et al. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Curr Med Res Opin. 2010;26:2679–87.PubMedGoogle Scholar
  60. 60.
    Horowitz J, Agarwal A, Huang F, et al. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm. 2009;15:741–50.PubMedGoogle Scholar
  61. 61.
    Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrol Dial Transplant. 2003;18:362–9.PubMedGoogle Scholar
  62. 62.
    Mann J, Kessler M, Villa G, et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clin Nephrol. 2007;67:140–8.PubMedGoogle Scholar
  63. 63.
    Tolman C, Richardson D, Bartlett C, et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol. 2005;16:1463–70.PubMedGoogle Scholar
  64. 64.
    Weiss LG, Clyne N, Divino FJ, et al. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled mulitcenter trial. Swedish Study Group. Nephrol Dial Transplant. 2000;15:2014–9.PubMedGoogle Scholar
  65. 65.
    Locatelli F, Baldamus CA, Villa G, et al. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis. 2002;40:119–25.PubMedGoogle Scholar
  66. 66.
    Lafeuille MH, Bailey RH, Vekeman F, et al. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease. Consult Pharm. 2010;25:493–500.PubMedGoogle Scholar
  67. 67.
    Rottembourg JB, Bridges I, Pronai W, et al. An observational study of the effectiveness of darbepoetin alpha administered to dialysis patients once every 2 weeks for 12 months. Clin Nephrol. 2011;75:242–50.PubMedGoogle Scholar
  68. 68.
    Feriani M, De Meester JMJ, McMahon LP, et al. Extended dosing of darbepoetin alfa in peritoneal dialysis patients. BMC Nephrol. 2011;12:13.PubMedGoogle Scholar
  69. 69.
    Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains haemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63:327–54.PubMedGoogle Scholar
  70. 70.
    Aranesp Summary of Product Characteristics. 2006 [online]. Available from URL: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000332/human_med_000651.jsp&mid=WC0b01ac058001d124 [Accessed 2012 Nov 26].
  71. 71.
    Galle J-C, Claes K, Kiss I, et al. An observational color study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrol Dial Transplant. 2012;27:2303–11.PubMedGoogle Scholar
  72. 72.
    Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.PubMedGoogle Scholar
  73. 73.
    Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.PubMedGoogle Scholar
  74. 74.
    Lim WH, Boudville N, Pellicano S, et al. Patients’ perceptions of subcutaneous delivery of darbepoetin alfa by autoinjector prefilled pen versus prefilled syringe: a randomized, crossover study. Clin Ther. 2012;34:1948–53.PubMedGoogle Scholar
  75. 75.
    Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211–5.PubMedGoogle Scholar
  76. 76.
    Jarsch M, Brandt M, Lanzendörfer M, et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008;81:63–9.PubMedGoogle Scholar
  77. 77.
    Koch M, Henrich D, Faust J, et al. Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trial. Clin Nephrol. 2012;78:189–97.PubMedGoogle Scholar
  78. 78.
    Levin NW, Fishbane S, Valdés Cañedo F, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007;370:1415–21.PubMedGoogle Scholar
  79. 79.
    Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637–46.PubMedGoogle Scholar
  80. 80.
    Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007;50:989–1000.PubMedGoogle Scholar
  81. 81.
    Spinowitz B, Coyne DW, Lok CE, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008;28:280–9.PubMedGoogle Scholar
  82. 82.
    Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008;3:337–47.PubMedGoogle Scholar
  83. 83.
    Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant. 2011;26:3980–6.PubMedGoogle Scholar
  84. 84.
    Canaud B, Mingardi G, Braun J, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008;23:3654–61.PubMedGoogle Scholar
  85. 85.
    Kessler M, Martinez-Castelao A, Siamopoulos KC, et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: the ARCTOS extension study. Hemodial Int. 2010;14:233–9.PubMedGoogle Scholar
  86. 86.
    Mann JF, de Francisco A, Nassar G, et al. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol. 2011;76:9–15.PubMedGoogle Scholar
  87. 87.
    Heidenreich S, Leistikow F, Zinn S, et al. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre. SUPRA study. Clin Drug Investig. 2012;32:99–110.PubMedGoogle Scholar
  88. 88.
    Leypolt JK, Loghman-Adham M, Jordan P, et al. Effect of hemodialysis and hemofiltration on plasma C.E.R.A. concentrations. Hemodial Int. 2012;16:20–30.Google Scholar
  89. 89.
    Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010;25:4009–17.PubMedGoogle Scholar
  90. 90.
    Minutolo R, Zamboli P, Chiodini P, et al. Conversion of darbepoetin to low doses of CERA maintains haemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purif. 2010;30:186–94.PubMedGoogle Scholar
  91. 91.
    Cano F, Alarcon C, Azocar M, et al. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol. 2011;26:1303–10.PubMedGoogle Scholar
  92. 92.
    Locatelli F, Mann JF, Aldigier JC, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol. 2010;73:94–103.PubMedGoogle Scholar
  93. 93.
    Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108:1830–4.PubMedGoogle Scholar
  94. 94.
    Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273:458–64.PubMedGoogle Scholar
  95. 95.
    Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006;34:1303–11.PubMedGoogle Scholar
  96. 96.
    Macdougall IC. Recent advances in erythropoietic agents in renal anemia. Semin Nephrol. 2006;26:313–8.PubMedGoogle Scholar
  97. 97.
    Omontys® (peginesatide) injection [prescribing information]. Palo Alto (CA): Affymax Inc, 2012.Google Scholar
  98. 98.
    Macdougall IC, Wiecek A, Tucker B, et al. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol. 2011;6:2579–86.PubMedGoogle Scholar
  99. 99.
    Besarab A, Zeig SN, Martin ER, et al. An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients. Nephrology. 2012;13:95.PubMedGoogle Scholar
  100. 100.
    Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. 2012;59:444–51.PubMedGoogle Scholar
  101. 101.
    Mikhail A. Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis. J Blood Med. 2012;3:25–31.PubMedGoogle Scholar
  102. 102.
    Woodburn KW, Schatz PJ, Fong KL, et al. Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys. Drug Chem Toxicol. 2008;31:229–44.PubMedGoogle Scholar
  103. 103.
    Woodburn KW, Fan Q, Winslow S, et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol. 2007;35:1201–8.PubMedGoogle Scholar
  104. 104.
    Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848–55.PubMedGoogle Scholar
  105. 105.
    Louët S. Lessons from Eprex for biogeneric firms. Nat Biotechnol. 2003;21:956–7.PubMedGoogle Scholar
  106. 106.
    Yang J. Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies. J Nephrol. 2005;18:102–5.PubMedGoogle Scholar
  107. 107.
    Jacob A, Sandhu K, Nicholas J, et al. Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant. 2006;21:2963–5.PubMedGoogle Scholar
  108. 108.
    Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant. 2007;22:1462–4.PubMedGoogle Scholar
  109. 109.
    Attaf DC, Torres PA. Not all new recombinant human erythropoietins are biosimilars [letter]. Kidney Int. 2009;74:441.Google Scholar
  110. 110.
    Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesis-stimulating agents: time for a reevaluation. N Engl J Med. 2010;362:189–92.PubMedGoogle Scholar
  111. 111.
    Szczech LA. Chronic kidney disease anemia management: what should be done? Blood Purif. 2011;31:186–8.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Division of Nephrology and Dialysis, Department of Medicine IIIMedical University of ViennaViennaAustria

Personalised recommendations